美国糖尿病市场

Market Overview:

The美国糖尿病市场reached a value of US$ 49.4 Billion in 2019. Looking forward, IMARC Group expects the market to exhibit moderate growth during 2020-2025. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use industries. These insights are included in the report as a major market contributor.

Diabetes, also referred to as diabetes mellitus, is a group of metabolic diseases in which a person suffers from high blood glucose. This can be either caused by the inappropriate response to insulin by the body, inadequate insulin production. If not monitored properly, diabetes can be fatal and cause serious health complications such as heart diseases, stroke, amputation, blindness and kidney diseases. According to the Centers for Disease Control and Prevention (CDC), more than 30 million adults have been diagnosed with diabetes or prediabetes in the United States. In 2018, the United States represented the third largest diabetes patient pool owing to the increasing geriatric population and rising obesity levels. Apart from this, physical inactivity and unhealthy lifestyle have further contributed to the escalating diabetic population.

The increasing diabetes prevalence has led the Government of US to launch diabetes prevention programs, raise awareness about its symptoms and encourage healthier lifestyle behavior amongst the citizens. In line with this, there has been a rise in diabetes diagnosis, monitoring and drug treatment rates. Moreover, the FDA has approved the production of Basaglar and Admelog, the biosimilar versions of insulin glargine and lispro. Several other diabetes drugs are also expected to gain approval in the coming years, which will further drive the growth of the market. Apart from this, rapid technological advancements have enabled the manufacturers to develop continuous glucose monitoring (CGM) device. It allows type-2 diabetes patients to check their blood periodically with the help of testing strips and easily monitor their blood sugar levels.

重点市场细分：

欧宝电竞首页IMARC集团提供了对美国糖尿病市场的每个子部分的关键趋势，以及2020-2025的预测。我们的报告基于分部对市场进行了分类。

Breakup by Segment:

• 胰岛素
• Oral Antidiabetics

At present, insulin exhibits a clear dominance over oral antidiabetics on account of the convenience and efficacy of insulin delivery devices. Amongst the various product types, long acting insulin represents the largest insulin class in the US, whereas DPP-IV inhibitors are the leading oral-antidiabetics class in the nation.

Competitive Landscape:

该报告审查了市场的竞争景观，并发现它与许多小型和大型制造商的存在性质很高。在市场上运营的一些关键球员是：

• 赛诺菲安万特美国服务公司。
• Novo Nordisk Inc.
• Eli Lilly and Company
• Merck＆Co. Inc。
• Zeneca Holdings Inc.
• Johnson & Johnson
  

我们在本报告中取得了什么：

Comprehensive situation analysis of the US diabetes epidemiology and its dynamics:

分析的重点：

• Historical, current and future prevalence of diabetes in the US
• Covid-19对美国糖尿病市场的影响
• Historical, current and future prevalence of type-1 and type-2 diabetes in the US
• 美国城乡地区糖尿病患者的历史，当前和未来患病率
• 美国男性和女性中糖尿病患者的历史，当前和未来患病率
• 美国各个年龄群中糖尿病患者的历史，当前和未来患病率
• Historical, current and future diagnosis rates for diabetes in the US
• 美国糖尿病的历史，当前和未来的药物治疗率
  

Comprehensive situation analysis of the US Oral Antidiabetics market and its dynamics:

分析的重点：

• 美国口头反赦免市场的表现
• Performance of key classes
• 关键参与者的表现
• 市场前景
  

Comprehensive situation analysis of the US Insulin market and its dynamics:

分析的重点：

• 美国胰岛素市场的表现
• Performance of key classes
• 关键参与者的表现
• 市场前景